Table 3.

Clinical presentation, course, and management of anticoagulation-associated ICH

Case	Cancer type	AC type*	ICH class†	ICH presentation‡	ICH course‡	PCC	Surgical management	ICU	AC management§	Death||
1	Lung	Apixaban	Measurable	1	1	No	No	No	Continue	No
2	Lung	Apixaban	Major	3	3	Yes	No	Yes	Stop	No
3	RCC	Apixaban	Measurable	1	1	No	No	No	Continue	No
4	RCC	Rivaroxaban	Major	3	3	Yes	No	Yes	Stop	No
5	Lung	Nadroparin	Major	3	1	No	No	No	Stop	Yes (+62)
6	Lung	Enoxaparin	Trace	1	1	No	No	No	Continue	No
7¶	Lung	Enoxaparin	Major	3	2	No	Yes	No	Hold (9 d)	No
8	Lung	Enoxaparin	Major	3	—	—	—	—	—	Yes (+14)
9	Thymic NEC	Enoxaparin	Major	3	1	No	No	No	Hold (2 d)	Yes (+21)
10¶	Lung	Enoxaparin	Major	3	—	—	—	—	—	Yes (+32)

AC, anticoagulation; ICU, intensive care unit; NEC, neuroendocrine carcinoma; PCC, prothrombin complex concentrate; RCC, renal cell carcinoma.

^*The anticoagulation dose at the time of ICH was therapeutic in 9 out of 10 cases (prophylactic in case 8), and no patients were receiving antiplatelet therapy.

^†Major indicates ICH ≥10 mL in volume, required surgical intervention, or was associated with symptoms; Measurable indicates ICH volume ≥1 mL but <10 mL; trace indicates ICH volume <1 mL or unmeasurable.

^‡Based on prespecified criteria as shown in supplemental Table 1, as reported by Bleker et al.¹⁸

^§Anticoagulation management at ICH. The number in parentheses indicates the number of days until anticoagulation was resumed after temporarily holding.

^||Death by 90 days post-ICH. The number in parentheses indicates the number of days between ICH and death.

^¶Incomplete follow-up data post-ICH.